PBAC's latest decision on Tislelizumab: Recommended with restriction (2024). Considered for First-line treatment of patients with unresectable, locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC) in combination with chemotherapy.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2024
Submissions
1
2024 → 2024
Eligible population
Adult patients with unresectable, locally advanced, recurrent, or metastatic oesophageal squamous cell carcinoma (OSCC) who are treatment-naïve to systemic therapy, with WHO performance status no higher than 1, receiving tislelizumab 200 mg every 3 weeks in combination with chemotherapy (platinum plus fluoropyrimidine or paclitaxel plus platinum).
Therapy area
Oncology
Line of therapy
First-line
Evidence base
RCT
Primary endpoint
OS
Pivotal trial size
649 patients
Key trials
RATIONALE-306, CheckMate-648, KEYNOTE-590
Comparator
nivolumab plus chemotherapy
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis (CMA) conducted; no ICER calculated by design. Effective price of nivolumab is confidential.